Published online May 14, 2022. doi: 10.3748/wjg.v28.i18.1981
Peer-review started: January 30, 2022
First decision: February 24, 2022
Revised: February 28, 2022
Accepted: March 26, 2022
Article in press: March 26, 2022
Published online: May 14, 2022
Processing time: 101 Days and 23.5 Hours
Fusobacterium nucleatum (F. nucleatum) has long been known to cause opportunistic infections and has recently been implicated in colorectal cancer (CRC), which has attracted broad attention. Exploring the roles and underlying mechanism of F. nucleatum has important theoretical and practical significance for diagnosis and targeted therapy of CRC.
The aim of this study is to reveal the effect of F. nucleatum infection on the changes of mucosal microbiota, and investigate the regulatory role of F. nucleatum in the CRC progression.
The azoxymethane/dextran sulfate sodium salt (AOM/DSS)-induced mice were used to investigate the role of F. nucleatum in the “oncogenic microbial environment” of the colon.
The mucosal microbial composition and RNA-seq transcriptomic analysis were used to identify the differentially expressed gene (DEG) signatures driven by F. nucleatum infection, and integrated network analysis was conducted to reveal the relationship between microbial dysbiosis and the DEGs.
We provide direct evidence that F. nucleatum interacts with other species, remodels the microbiota, and alters the tumor microenvironment. In addition, we revealed the dysbiosis signature of the colon mucosa microbiota driven by F. nucleatum and the interaction between the hub microbial taxa and the host transcriptome.
Dysbiosis in the mucosal microbiota driven by F. nucleatum, in particular Enterobacteriaceae and Stenotrophomonas, occurs during F. nucleatum infection, leading to the differential expression of oncogene transcriptomes in the AOM/DSS model.
Our study provides a deeper insight into CRC etiology driven by F. nucleatum infection and the mechanisms of the tumorigenic effect of F. nucleatum. Targeting F. nucleatum infection is a potential treatment for CRC.